Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bjorn L Millard

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Nature Methods|April 26, 2011
Adaptive informatics for multifactorial and high-content biological dataBjorn L Millard, Mario Niepel, Michael P Menden, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 29, 2019
Quantitative Systems Pharmacology Model of a Masked, Tumor-Activated AntibodyMark Stroh, Jason Sagert, John M Burke, et al.
Current Opinion in Toxicology|January 9, 2018
Quantitative systems toxicologyPeter Bloomingdale, Conrad Housand, Joshua F Apgar, et al.
Clinical Pharmacology and Therapeutics|July 19, 2020
Model-Informed Drug Development of the Masked Anti-PD-L1 Antibody CX-072Mark Stroh, Michelle Green, Bjorn L Millard, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 12, 2018
Quantitative Systems Pharmacology Model of hUGT1A1-modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler-Najjar Syndrome Type 1Joshua F Apgar, Jian-Ping Tang, Pratap Singh, et al.
Cancer Immunology Research|January 6, 2025
NI-3201 Is a Bispecific Antibody Mediating PD-L1-Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor ControlSara Majocchi, Pauline Lloveras, Lise Nouveau, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Nature Methods|April 26, 2011
Adaptive informatics for multifactorial and high-content biological dataBjorn L Millard, Mario Niepel, Michael P Menden, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 29, 2019
Quantitative Systems Pharmacology Model of a Masked, Tumor-Activated AntibodyMark Stroh, Jason Sagert, John M Burke, et al.
Current Opinion in Toxicology|January 9, 2018
Quantitative systems toxicologyPeter Bloomingdale, Conrad Housand, Joshua F Apgar, et al.
Clinical Pharmacology and Therapeutics|July 19, 2020
Model-Informed Drug Development of the Masked Anti-PD-L1 Antibody CX-072Mark Stroh, Michelle Green, Bjorn L Millard, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 12, 2018
Quantitative Systems Pharmacology Model of hUGT1A1-modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler-Najjar Syndrome Type 1Joshua F Apgar, Jian-Ping Tang, Pratap Singh, et al.
Cancer Immunology Research|January 6, 2025
NI-3201 Is a Bispecific Antibody Mediating PD-L1-Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor ControlSara Majocchi, Pauline Lloveras, Lise Nouveau, et al.
Pageof 1